Golden Lee Scott, who serves as Executive Vice President and Chief Medical Officer at PTC Therapeutics, INC. (NASDAQ:PTCT), disposed of 829 shares of the company's common stock on April 2, 2026. The shares were sold at $67.99 per share, producing a gross transaction value of $56,363. The sale was carried out specifically to meet tax withholding obligations arising from the vesting of 2,100 Restricted Stock Units that were granted on April 24, 2023.
After the disposition, Scott's direct ownership of PTC Therapeutics common stock stands at 79,115 shares. The sale represents a routine tax-related transaction tied to equity compensation vesting rather than an unsolicited market repositioning.
PTC Therapeutics has delivered notable market performance over the prior year, with shares rising 57 percent over that period. At the same time, InvestingPro's analysis, as referenced by the company update, assesses the stock as slightly overvalued relative to its Fair Value estimate at prevailing prices. The platform also notes the availability of extended analysis and nine additional ProTips for investors who wish to dig deeper into the company metrics on that service.
On the corporate reporting front, PTC Therapeutics pre-announced its fourth-quarter 2025 earnings and disclosed full-year 2025 revenue figures last month. The company also provided guidance for fiscal 2026 earlier in January, offering investors forward-looking financial context ahead of its regular reporting cadence.
However, PTC encountered a regulatory setback when it withdrew its New Drug Application resubmission for Translarna, a therapy intended for nonsense mutation Duchenne muscular dystrophy. The withdrawal followed feedback from the U.S. Food and Drug Administration indicating that the resubmission did not contain substantial evidence of effectiveness sufficient for approval consideration.
Following the earnings and regulatory updates, several sell-side firms adjusted or reiterated their views. Morgan Stanley increased its price target for PTC Therapeutics to $92 and maintained an Overweight rating, citing reductions in operating expenditures. Cantor Fitzgerald reaffirmed an Overweight rating and set a price target of $124 in the wake of the earnings release. Barclays entered coverage with an Overweight rating and a $119 price target, highlighting the potential of the company’s phenylketonuria treatment.
In governance developments, PTC Therapeutics appointed Jessica Chutter to its board of directors. The company notes Chutter's prior experience at Morgan Stanley as relevant to her board role.
This report consolidates the disclosed insider transaction, recent corporate results and guidance, the regulatory decision on Translarna, analyst coverage changes, and a board appointment into a single update for investors tracking PTC Therapeutics.